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ABSTRACT 36 
Antibiotic resistant strains of Acinetobacter baumannii are responsible for a large and 37 
increasing burden of nosocomial infections in Thailand and other countries of Southeast Asia. 38 
New approaches to their control and treatment are urgently needed and an attractive strategy is 39 
to remove the bacterial polysaccharide capsule, and thus the protection from the host’s immune 40 
system. To examine phylogenetic relationships, distribution of capsule chemotypes, acquired 41 
antibiotic resistance determinants, susceptibility to complement and other traits associated with 42 
systemic infection, we sequenced 191 isolates from three tertiary referral hospitals in Thailand 43 
and used phenotypic assays to characterise key aspects of infectivity. Several distinct lineages 44 
were circulating in three hospitals and the majority belonged to global clonal group 2 (GC2). 45 
Very high levels of resistance to carbapenems and other front-line antibiotics were found, as 46 
were a number of widespread plasmid replicons. A high diversity of capsule genotypes was 47 
encountered, with only three of these (KL6, KL10 and KL47) showing more than 10% 48 
frequency. Almost 90% of GC2 isolates belonged to the most common capsule genotypes and 49 
were fully resistant to the bactericidal action of human serum complement, most likely 50 
protected by their polysaccharide capsule, which represents a key determinant of virulence for 51 
systemic infection. Our study further highlights the importance to develop therapeutic 52 
strategies to remove the polysaccharide capsule from extensively drug-resistant A. baumanii 53 
during the course of systemic infection. 54 
INTRODUCTION 55 
A. baumannii is an opportunistic pathogen that can cause potentially lethal nosocomial 56 
infections (Howard et al., 2012). These are frequently a result of trauma, surgery, 57 
catheterisation or endotracheal intubation (Chopra et al., 2014), and A. baumannii can escape 58 
the local immune reaction by evading neutrophils, macrophages and complement (C') (Russo 59 
et al., 2008; García-Patiño et al., 2017). This immune escape therefore necessitates the use of 60 
antimicrobials, and the key determinant of clinical outcome of A. baumannii infection is 61 
treatment failure due to the high number of antibiotic resistant strains (Wong et al., 2017). 62 
Multidrug resistant (MDR) strains of A. baumannii have spread rapidly over recent decades 63 
(Zarrilli et al., 2013; Hamidian and Nigro, 2019). The high prevalence of strains resistant to 64 
nearly all antibiotics, especially well-tolerated cephalosporins and carbapenems, has led to the 65 
revival of drugs considered to be of last resort such as polymyxins (Falagas and Kasiakou, 66 
2005; Sahbudak Bal et al., 2018) for systemic administration. However, resistance to colistin 67 
is now more prevalent and polymyxins are now used less widely due to serious side effects 68 
associated with these agents (Sahbudak Bal et al., 2018). As a consequence, the World Health 69 
Organisation has identified carbapenem-resistant A. baumannii (CRAB) as the greatest 70 
bacterial threat to global human health and the top priority pathogen for development of new 71 
antibiotics (Tacconelli et al., 2018).  72 
Recent surveillance data indicates that A. baumannii causes under 2% of healthcare associated 73 
infections in the USA (Sievert et al., 2013; Bulens et al., 2018) but prevalence is much higher 74 
in Southern and South Eastern Asia, where it is frequently the major nosocomial infectious 75 
agent (Suwantarat and Carroll, 2016). The burden of A. baumannii infection is particularly 76 
severe in Thailand, with isolates accounting for 15-16% of hospital-acquired bacteraemia cases 77 
and displaying very high levels (70-88%) of carbapenem resistance, and mortality rates in 78 
excess of 60% due to MDR A. baumannii bacteraemia (Chaisathaphol and Chayakulkeeree, 79 
2014; Suwantarat and Carroll, 2016; Hsu et al., 2017; Hongsuwan et al., 2014; Sirijatuphat et 80 
al., 2018). Presence of the over-expressed carbapenemase blaOXA-23, or blaOXA-51 in 81 
combination with IS elements, account for most of the CRAB phenotypes (Figueiredo et al., 82 
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2009; Teo et al., 2015; Wong et al., 2017). Molecular typing identified three European clones; 83 
two have spread globally and are now identified as GC1 and GC2 (Higgins et al., 2010; 84 
Hamidian and Nigro, 2019) and the majority of isolates from Asia belong to global clone 2 85 
(GC2) (Kim et al., 2013; Kamolvit et al., 2015). 86 
The large majority of A. baumannii strains produce a substantial capsular polysaccharide that 87 
protects them from external threats (Kenyon and Hall, 2013), and an attractive treatment option 88 
is enzymatic removal of the protective capsules (Merabishvili et al., 2017; Mushtaq et al., 2004; 89 
Lin et al., 2014; Negus et al., 2015); capsule-free mutants were highly susceptible to C'-90 
mediated attack (Lees-Miller et al., 2013), in marked contrast to their encapsulated parent 91 
strains. A major advantage of this approach is that it circumvents the accumulation of antibiotic 92 
resistance determinants, but has the potential disadvantage that variation of the capsular 93 
polysaccharide may limit the utility of individual depolymerases as found in bacteriophages or 94 
other organisms, which typically hydrolyse only one or a limited number of capsular types 95 
(Hernandez-Morales et al., 2018; Oliveira et al., 2017; Singh et al., 2018).  96 
We report a detailed characterisation of 191 recent isolates from three major hospitals in 97 
Thailand using whole-genome sequencing and functional assays, with particular reference to 98 
their surface properties and antibiotic resistance profiles. We also sought to identify factors that 99 
contribute to the capacity of GC2 isolates to cause infection through  increased virulence 100 
(Zarrilli et al., 2013), using genomic data and bioassays, in relation to the role of the capsule in 101 
the determination of resistance to C'-mediated attack. 102 
METHODS 103 
Bacterial isolates 104 
A total of 191 A. baumannii isolates were cultured from wound pus, sputum, urine, blood, and 105 
excised tissue at the clinical microbiology laboratories of three tertiary referral hospitals in 106 
Thailand (Figure 1A). Bacteria were initially identified by routine biochemical tests 107 
implemented for identification of Gram-negative bacteria. Species were further confirmed by 108 
whole-genome sequencing and sequence typing as below. The hospitals were Thammasat 109 
University Hospital, Pathum Thani Province (47 isolates; April 2016), Siriraj Hospital, 110 
Bangkok (84 consecutive isolates; April 2016) and Songklanagarind Hospital, Hat Yai, 111 
Songkhla Province (60 isolates; August 2016). Siriraj is the largest hospital in Thailand with 112 
2,300 beds, 1,000,000 outpatients per annum and 80,000 inpatients per annum; equivalent 113 
figures for Songklanagarind are 846, 1,019,375 and 40,936 and for Thammasat 601, 384,088 114 
and 40,745 (data from 2017). Details of these isolates are given in Supplementary Table S1. 115 
Susceptibilities to clinically relevant antibiotics were determined using the Vitek 2 system 116 
(Bosshard et al., 2006). 117 
Genome sequencing, assembly and annotation 118 
Genomic DNA was extracted and sequenced using Illumina-B HiSeq X paired-end sequencing. 119 
Annotated assemblies were produced according to (Page et al., 2016a). Sequence reads were 120 
assembled de novo with Velvet v1.2 (Zerbino and Birney, 2008) and VelvetOptimiser v2.2.5 121 
(Seemann and Gladman). Reads were annotated using PROKKA v1.11 (Seemann, 2014). The 122 
stand-alone scaffolder SSPACE (Boetzer et al., 2011) was used to refine contig assembly; 123 
sequence gaps were filled using GapFiller (Boetzer and Pirovano, 2012). Genomes with greater 124 
than 5% contamination levels as determined by Kraken (Wood and Salzberg, 2014), fully 125 
assembled genomes of less than 4.5 Mpb or comprising 500 or more contigs were removed.  126 
Putative genomes with less than 60% sequence similarity with the reference genome were 127 
assessed with CheckM (Parks et al., 2015) for genome completeness and contamination; 128 
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isolates with greater than 3% contamination levels were excluded from the study. SNPs were 129 
called against the A. baumannii reference genome to identify heterozygous SNPs, and isolates 130 
with more than 2% were removed from further analysis (Page et al., 2016a), resulting in the 131 
191 genomes analysed in this study. As we could also observe several gdhB duplicate 132 
sequences, a known problem of the Oxford MLST scheme (Bartual et al., 2005; Gaiarsa et al., 133 
2019), sequence types were assigned and are reported only based on the Pasteur scheme 134 
(Diancourt et al., 2010; J. Page et al., 2016). Novel sequence types were assigned for non-135 
typeable isolates through the PubMLST (Supplementary Table S1), three isolates could not 136 
be assigned as the assemblies were missing one allele. 137 
Phylogenetic analyses 138 
The pan genome for the global and Thai isolate analyses was determined with Roary (Page et 139 
al., 2015) using a Protein BLAST identity of 95% and a core definition of 99%. SNPs were 140 
extracted from the core gene alignment using SNP sites (Page et al., 2016b) and the output used 141 
to run RAxML v8.2.8 (Stamatakis, 2014) to calculate the phylogenetic tree with 100 bootstraps 142 
under the GTR time-reversible model. The resulting alignment for the global dataset was also 143 
used to determine pairwise SNP distances with the dist.gene function from the ape package in 144 
R (Paradis et al., 2004). To place our isolates in a broader context, we compared them with 145 
recently published sequence data of A. baumannii causing ventilator-associated pneumonia in 146 
the intensive care unit of a Vietnamese hospital, in addition to data from several other published 147 
studies (Supplementary Table S2). 148 
Antibiotic resistance and traits associated with infection  149 
Antibiotic resistance genes were detected with the curated version of the ARG-ANNOT 150 
database available at the SRST2 site (Inouye et al., 2014; Gupta et al., 2014), rpoB SNP 151 
mutations were assessed comparing the sequences against described resistance mutations 152 
(Giannouli et al., 2012; Pérez-Varela et al., 2017), and virulence factors with VFDB (Chen et 153 
al., 2016), using the read-based search program ARIBA (Hunt et al., 2017). Plasmid replicons 154 
were detected with a custom database composed of 30 genes involved in plasmid replication, 155 
stabilisation and mobilisation from Acinetobacter plasmids (Bertini et al., 2010; Salto et al., 156 
2018); some additional plasmids (Gao et al., 2011; Hamidian et al., 2012; Zhang et al., 2013; 157 
Jones et al., 2014; Hamidian et al., 2016; Hamidian et al., 2017; Blackwell and Hall, 2017) 158 
were also included (full database Supplementary file S1); and analyses were undertaken using 159 
ARIBA software v2.12.1 (Hunt et al., 2017). To account for potential variation in surface 160 
proteins or other virulence factors, a custom-made collection of A. baumannii virulence factors 161 
(Table S6) was searched against our isolates using phmmer (Eddy, 2011; Weber et al., 2015; 162 
Lee et al., 2017; Scott et al., 2014; Eijkelkamp et al., 2011; Eijkelkamp et al., 2014; Harding et 163 
al., 2013). Representations of trees and metadata were performed using iTOL (Letunic and 164 
Bork, 2016) and the ggplot2 and ggtree packages in R (Wickham, 2009; Yu et al., 2018). KL 165 
and OCL genotypes of our isolates were identified using the capsule identification program 166 
kaptive, based on a curated A. baumannii specific database (Wyres et al., 2019; Table S1).  167 
C' susceptibility  168 
Commercial (MP Biomedicals UK) pooled human serum was stored and used to determine 169 
susceptibility to C', essentially as previously described (Loraine et al., 2018). Early mid-170 
logarithmic-phase Luria-Bertani (LB) broth cultures of A. baumannii were washed three times 171 
with 200 μl of gelatin-veronal-buffered saline containing Mg2+ and Ca2+ (GVB++; pH 7.35) and 172 
suspended in 400 μl of GVB++. The suspensions (200 µl) were mixed with 390 μl of pre-173 
warmed (37˚C) normal human serum to give a final concentration of ~1 x 106 CFU, the 174 
mixtures incubated at 37°C for 3 h and bacteria quantified by serial dilution and overnight 175 
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incubation on LB agar (see Supplementary Table S3 for all raw data). The 45 GC2 isolates 176 
were exposed to 66% normal human serum and enumerated bacterial survivors over a 3 h 177 
incubation period (Malke, 1986).  Isolates were assigned to one of three categories: resistant 178 
(R), showing no (or only transient) reduction in viable count during the incubation period; 179 
delayed susceptible (DS), displaying significant (~90%) survival after 1 h and low survival 180 
(<10%) after 3 h incubation; the inocula of rapidly susceptible (S) isolates were reduced to 181 
below 10% after 1 h incubation. All experiments were performed in duplicate and results 182 
expressed as percent survival over this time period. Pre-warmed, heat-inactivated human serum 183 
(56oC, 30 min) served as control. All raw data is given in Supplementary Table S3. 184 
Capsule measurements 185 
The size of the capsule for each isolate was determined by negative staining with India ink, 186 
microscopic imaging and calculation of the area occupied by the capsule using CellProfiler 187 
image analysis software (v3.1.9; Lamprecht et al., 2007). One bacterial colony was 188 
resuspended in PBS and mixed in a 1:1 ratio with India Ink stain (BD India Ink Reagent 189 
Dropper) and applied to a microscope slide with a coverslip. Microscopic imaging with a Zeiss 190 
Axiostar plus transmitted light microscope fitted with an Olympus SC30 digital camera and 191 
using a 100× oil immersion lens and embedded scale bar. All raw data is given in 192 
Supplementary table S4. 193 
 194 
Motility  195 
Swarming and twitching motility were assayed by the subsurface agar method (Clemmer et al., 196 
2011) using LB broth containing either 0.4 or 0.8% agar. Briefly, freshly grown cultures of A. 197 
baumannii were stabbed to enable spread of bacteria on the surface of 0.4% agar plates for 198 
swarming motility and the interphase between the bottom of the Petri dish and the 0.8% agar 199 
layer for twitching motility. The plates were incubated at 37°C for 48 h: positive swarming 200 
motility was defined as a zone greater than 10 mm around the site of inoculation. For twitching 201 
motility at the interstitial surface between the agar and the petri dish, the agar was discarded, 202 
and bacteria visualised by staining stained with 0.2% crystal violet. Positive twitchers were 203 
defined as those cultures that showed a zone diameter greater than 5 mm. Assays were 204 
performed a minimum of three times for each isolate. All raw data is provided in 205 
Supplementary Table S5. 206 
 207 
RESULTS 208 
Major lineages are circulating in the region 209 
Phylogenetic analysis identified several lineages circulating in all the three hospitals (Figure 210 
1A and B). The majority of isolates belong to GC2 (n=106/191), represented exclusively by 211 
sequence type 2 (ST2) of the Pasteur scheme. No isolates belonging to GC1 were identified, a 212 
key clonal group in the evolution of multi-drug resistance in A. baumannii (Holt et al., 2016). 213 
Non-GC2 isolates belonged to ST164 (n=14; 7.3%), ST215 (n=13; 6.8%), ST16 (n=9; 4.7%), 214 
ST25 (n=6; 3.1%), ST129 (n=6; 3.1%), ST374 (n=4; 2.1%) and ST10 (n=2; 1.0%); three 215 
isolates could not be sequence-typed, most likely due to low-quality genomes, and thus missing 216 
one of the MLST alleles. The high prevalence of GC2 and lack of GC1 of our dataset from 217 
2016 closely resembles the population structure from the Vietnamese hospital outbreak 218 
(Schultz et al., 2016) over the period 2009-12 (Figure 1C); both datasets include a considerable 219 
number of deep branching lineages. These similarities in population structure are also mirrored 220 
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when comparing the distribution of pairwise single-nucleotide polymorphisms (SNPs) between 221 
the datasets from Vietnam and Thailand (Figure 1D). 222 
Antimicrobial resistance 223 
Phenotypic resistance profiles for 115 of the strains confirmed the very high levels of antibiotic 224 
resistance encountered with clinical isolates of A. baumannii, especially against β-lactam 225 
agents (e.g., ceftriaxone: 115/115, 100%), including carbapenems (Fig. 2a; 98/115, 85.2%), 226 
but also against other major antibiotic classes: fluoroquinolones (98/115, 85.2% resistant / 227 
intermediate [R/I]), aminoglycosides (79/115, 68.7% R/I) and trimethoprim (76/115, 66.1% 228 
R/I), and multidrug resistance was, as expected, associated with a high number of acquired 229 
resistance genes (Figure 2A, C; Supplementary Figures S1, S2) indicating either gain 230 
through larger elements carrying several genes as previously described as a key driver for A. 231 
baumannii resistance (Bonomo and Szabo, 2006; Post and Hall, 2009). blaOXA23, the most 232 
prominent carbapenem resistance gene, is present in 85.2% of imipenem resistant strains 233 
(Figure 2C). Few isolates carried the blaNDM-1 gene and a low number of acquired ampC genes 234 
were detected (Figure 2C, S2). We also note the presence of the arr gene, as well as rpoB 235 
mutations, conferring rifampicin resistance, one of the last line antimicrobials used against 236 
CRAB (Thapa et al., 2009; Durante-Mangoni et al., 2014). 237 
Mobile elements 238 
All but ten isolates contained at least one of the plasmid replicons (supporting file S1) and 121 239 
contained two to maximal five (Figure 2B). The three plasmid replicons detected at highest 240 
frequency were RepAci1, RepAci6 and RepApAB49. Each of these plasmid types were found 241 
across a number of STs, although RepAci1 plasmids were present in almost all the ST2 isolates 242 
(102/106) and RepApAB49 was found in 12/14 ST164 isolates. Recently, a RepAci1 plasmid 243 
was shown to be mobilised by a co-residing conjugative RepAci6 plasmid (Blackwell and Hall, 244 
2019), and these two replicons co-occur in the genomes of 56 isolates; RepAci6 only was 245 
detected in one isolate, and RepAci1 only in 46. RepAci6 plasmids were the most common 246 
self-transmissible plasmids detected. Plasmid replicons detected frequently included those 247 
matching pRAY*, which is often associated with the aadB gene (Hamidian et al., 2012), 248 
RepAci3, p3ABAYE, pABTJ2 and RepAci9. RepMAci9 was detected in all thirteen ST215 249 
isolates. Seven plasmid types were present in low frequency (Figure 2B) and an additional 250 
fifteen plasmid sequences were not detected in the Thai collection (supporting file S1). 251 
Genes associated with capsules and outer core 252 
A. baumannii does not contain genes involved in lipopolysaccharide (LPS) O-antigen ligase 253 
activity (Kenyon and Hall, 2013; Weber et al., 2015), synthesising instead a 254 
lipooligosaccharide (LOS) consisting of an outer core oligosaccharide (OCL) linked to Lipid 255 
A (Kenyon and Hall, 2013; Kenyon et al., 2014a); at least twelve distinct OCL structures have 256 
been inferred from genomic data  (Kenyon et al., 2014b). We mapped all Thai isolates against 257 
an A. baumannii specific databases for capsular and LOS loci (KL and OCL, resp.; 258 
Supplementary Figure S3; Wyres et al., 2019). In similar fashion to the Vietnam study 259 
(Schultz et al., 2016), we noted a high diversity of KL within both GC2 and non-GC2 isolates. 260 
KL6 (15.2%), KL10 (15.7%), KL47 (11.0%), KL2 (8.4%), KL52 (7.9%), KL3 (7.3%), KL49 261 
(6.3%), KL24 (5.8%), KL14 (3.1%) and KL28 (2.1%) were frequently encountered and KL32, 262 
KL63, KL57, KL8, KL108, KL19, KL113, KL116, KL60, KL43, KL37, KL9, KL125 and KL7 263 
were represented in 2% or fewer isolates. KL could not be determined in 15 isolates (7.9%). 264 
KL2 and KL49 were found at least twice in the Vietnam isolates although we did not detect 265 
KL58, strongly represented in (Schultz et al., 2016). Eight distinct capsule loci in our GC2 266 
isolates were detected in isolates from all three hospitals during April 2016 and provide a 267 
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challenge for novel therapies targeting bacterial cell surfaces. Furthermore, seven distinct LOS 268 
loci were detected amongst the Thai isolates (Supplementary Figure S3, Table S1). The 269 
majority of GC2 isolates carried genes for OCL1 biosynthesis (91 isolates, 85.8% of all GC2 270 
isolates, 61.8% total), whilst the other types, OCL2 (6.8%), OCL3 (4.2%), OCL4 (1.6%), 271 
OCL5 (15.7%), OCL6 (4.7%) and OCL7 (5.2%) were also widely distributed amongst our 272 
isolates; there was however no clear association between K- and LOS-types (Figure 3). 273 
Linking virulence-associated phenotype, site of isolation, and genotype in GC2 274 
We examined 45 GC2 isolates belonging to the major capsule types identified in the Thai 275 
collection: KL10 (eight isolates), KL2 (4), KL3 (2), KL47(2), KL49 (5), KL52 (2) and KL6 276 
(22). Although A. baumannii strains lack flagella, the species displays type IV-mediated 277 
twitching motility that facilitates spreading on abiotic surfaces (Vijayakumar et al., 2016), and 278 
it has been linked to the capacity of strains to cause systemic infection (Harding et al., 2018). 279 
Only six of our 45 GC2 isolates were derived from blood samples but all displayed twitching 280 
motility (Table 1, Table S5, Figure 3A). In contrast, none of six tissue isolates and only a 281 
minority of sputum isolates (10/33) were motile in this fashion. The capacity to swarm on semi-282 
solid agar, (surface-associated motility;  Harding et al., 2018) can also be linked to a more 283 
virulent phenotype (Tipton and Rather, 2017; Eijkelkamp et al., 2011). 24/45 of the Thai GC2 284 
isolates displayed surface-associated (swarming) motility; 6/6 of these were from tissue 285 
samples and 18/33 from sputum (Table 1, Figure 3A). Three isolates from sputum exhibited 286 
both forms of motility. 287 
Many loci that have been linked to the capacity of A. baumannii to colonise, invade and 288 
disseminate within the host, such those encoding adhesins, capsules, quorum sensors, iron 289 
sequestering systems and other nutrient scavengers (Harding et al., 2018), are essential or 290 
advantageous for survival in its natural habitat, predominantly soil and water (Baumann et al., 291 
1968). The distribution of genes based on a publicly available virulence factor database is 292 
shown in Supplementary Figure S4, but whilst there are clear differences, no trend (for 293 
example increased prevalence in GC2) could be observed. As expected, siderophores, adhesins 294 
involved in biofilm formation and maintenance, and a variety of genes determining capsule 295 
biosynthesis are widely distributed among the isolates. 296 
GC2 capsule size correlates with survival in human serum 297 
A large proportion (40/45, 88.9%) were refractory to C'-mediated killing; of the remainder, 298 
only four were categorised as S (Table 1). All KL10, KL3, KL47, KL49 and KL52 isolates 299 
belonged to the R group, with only KL2 (2/4) and KL6 (3/23) capsule types displaying any 300 
degree of C' susceptibility (Figure 3A, B). All 45 GC2 isolates examined were encapsulated. 301 
The C' susceptible isolates elaborated significantly smaller capsules than R A. baumannii (R, 302 
mean 1.62 mm2; DS, 0.31 mm2; S, 0.81 mm2); all capsule locus predictions however showed a 303 
perfect or almost perfect match, emphasizing that the capsule biosynthesis locus is likely intact. 304 
(Figure 3A) Capsules containing sialic acids protect Gram-negative bacteria from C' attack 305 
(Rautemaa and Meri, 1999), and N-acetylneuramininc acid and related nonulosonic and sialic 306 
acid structures have recently been found as repeat-unit constituents or as modifications of 307 
capsule structures in hypermucoviscous K. pneumoniae (Lin et al., 2014) and A. baumannii 308 
(Vinogradov et al., 2014; Kenyon et al., 2015; Singh et al., 2018), and associated with increased 309 
infectivity. Biosynthesis of sialic acids begins with the conversion of UDP-N-310 
acetylglucosamine to UDP and N-acetylmannosamine by the hydrolysing 2-epimerase NeuC; 311 
a homologue of this enzyme has been described for A. baumannii and its crystal structure 312 
determined (Ko et al., 2018). In our set of genomes, the neuC homologue 313 
(A0A154EJU5_ACIBA) was found only in the genomes of the five C' resistant isolates 314 
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carrying genes for biosynthesis of the K49 capsular polysaccharide and is indeed a component 315 
of the KL49 locus and should thus correctly be annotated as lgaC; the repeat unit of the K49 316 
capsular polysaccharide is composed of  α-L-fucosamine, α-D-glucosamine and the 317 
nonulosonic acid α-8-epi-legionaminic acid (Vinogradov et al., 2014).  318 
OmpA, one of most abundant porins, is also known to bind factor H in human serum (Kim et 319 
al., 2009), and implicated to prevent C’ mediated killing; it is however present in all our GC2 320 
strains (Figure S4). A more detailed analysis of putative factors explaining the phenotypes 321 
(type IV pili, surface proteins, secretion systems, biofilm formation; (Weber et al., 2015; Lee 322 
et al., 2017; Table S6) of the 47 GC2 isolates showed no differences that correlated with any 323 
of the phenotypes tested. We also included sequence analyses of PilA, which has been shown 324 
to influence twitching motility (Ronish et al., 2019); however, the sequences from all 325 
phenotyped isolates were identical.  326 
 327 
DISCUSSION 328 
Multi-drug resistant A. baumannii infections are rapidly increasing and require the use of last-329 
line treatments such as colistin. An additional challenge further narrowing the spectrum of 330 
available options for highly resistant A. baumannii infections is that last-line treatments 331 
available often overlap with other highly problematic infections. One example is the use of 332 
rifampicin in combination with colistin against CRAB, which is also one of the last options to 333 
treat the increasing number of multi-drug resistant tuberculosis (MDR TB) cases, and use of 334 
rifampicin is therefore restricted in use against organisms other than MDR TB (Seijger et al., 335 
2019; Leite et al., 2016; Durante-Mangoni et al., 2014; Thapa et al., 2009). There is therefore 336 
a growing interest in the potential of non-antibiotic therapeutic approaches including 337 
bacteriophage-derived capsule depolymerases as treatment alternative to antimicrobial 338 
chemotherapy (Seijger et al., 2019; García-Quintanilla et al., 2013; Waldor et al., 2005).  339 
We present the analysis of a set of 191 A. baumannii clinical isolates from three major hospitals 340 
in Thailand with very high levels of drug resistance. The population structure is biased towards 341 
the major clone GC2, as has been observed in other studies in geographic proximity (Schultz 342 
et al., 2016). However, the inter-mixed origins of closely related isolates from all three 343 
hospitals clearly indicates that both GC2 as well as less dominant sequence types are circulating 344 
in the region, and are frequently (re)introduced into hospitals, as opposed to a clonal outbreak 345 
within one hospital. In addition to the phylogenetic diversity (almost 50% non-GC2 isolates) 346 
and the even spread across the three hospitals, we show that there is a high degree of strain-to-347 
strain capsule variability, and development of depolymerase therapeutics will need to account 348 
for the challenge of a wide range of capsule types. Nevertheless, a recent study has 349 
demonstrated the potential of capsule depolymerase against A. baumannii in a Galleria 350 
mellonella (wax moth) larvae infection model and protection of both normal and 351 
immunocompromised mice from lethal peritoneal sepsis (Liu et al., 2019a).  352 
The enzyme also sensitised the C'-resistant isolate to serum (Liu et al., 2019b), which is highly 353 
relevant as the large majority of our GC2 isolates (40/45) were C' resistant, in similar 354 
proportion to other recent studies (Skerniškytė et al., 2019; Sanchez-Larrayoz et al., 2017). 355 
LPS O-side chains prevent assembly of the C5b-9 complex by steric hindrance; A. baumannii 356 
however does not decorate its LOS with O-side chains but is able to modify the lipid A moiety 357 
of LOS by acylation, resulting in increased survival in blood (Bartholomew et al., 2019), which 358 
could prevent C5b-9 intercalation into the bilayer. Alternatively, there is some evidence that A. 359 
baumannii may prevent C' activation: resistant clinical isolates bound fH, a key inhibitor of the 360 
alternative C' pathway (Kim et al., 2009), preventing C5b-9 generation. King et al. (King et al., 361 
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2009) found that clinical isolates did not bind fH but circumvented C3b deposition, again 362 
preventing C5b-9-mediated bacterial killing. Cell surface-located sialic acids are potent 363 
recruiters of fH and we therefore examined Thai GC2 isolates for evidence of neuC-dependent 364 
sialyl biosynthesis. The neuC homologue is part of the KL49 locus; however, nonulosonic acid 365 
sugars are also found in the K2 and K6 types (Kenyon and Hall, 2013), which have C’ sensitive 366 
as well as resistant phenotypes.  367 
Current evidence indicates that C' killing of susceptible A. baumannii proceeds predominantly 368 
through the activation of the alternative pathway (Kim et al., 2009; Jacobs et al., 2010; 369 
Sanchez-Larrayoz et al., 2017). The lack of classical pathway killing may be due to the absence 370 
of C'-activating IgG or IgM directed against A. baumannii surface structures in normal human 371 
serum, suggesting that the predominant means to avoid bactericidal effects is prevention or 372 
subversion of activation of the alternative pathway. It is likely that the polysaccharide capsule 373 
is the predominant macromolecule facilitating C' resistance (Harding et al., 2018) and the four 374 
fully C' susceptible isolates in the current study elaborated less capsule than the resistant group. 375 
Capsule depolymerases as an alternative means of resolving A. baumannii systemic infections 376 
would thus be worth exploring but may be limited by the wide diversity of capsule types likely 377 
to be encountered in current clinical isolates.  378 
Whilst the current focus is placed on GC2, it is important to point out that GC1 and GC2 seem 379 
to follow different strategies for interacting with the immune system and hospital environment. 380 
Whilst we report low motility and high C’ resistance for GC2 and the associated genetic 381 
background, GC1 seems to follow a very different route, with high motility profiles and 382 
different adherence profiles than GC2 (Skerniškytė et al., 2019). It is thus crucial to increase 383 
active surveillance of A. baumannii epidemiology, as different high-risk lineages may need 384 
different approaches to reduce their burden in the clinic. 385 
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 778 
FIGURE LEGENDS 779 
FIGURE 1. The population structure of A. baumannii isolated from a variety of infections in 780 
April 2016 at three major Thai hospitals. (A) Samples were obtained from geographically 781 
distinct regions of the country. (B) Core gene phylogeny showed that the bacterial populations 782 
were circulating amongst the three hospitals; no single lineage dominated at any one location. 783 
(C) Our data in context with the global population structure based on published data. (D) A 784 
more detailed comparison of the data structure of pairwise SNP distances shows a similar 785 
distribution between our samples and a recent study from one hospital in Vietnam (Schultz et 786 
al., 2016), with a similarly high prevalence of ST2 (C), but also a considerable number of more 787 
distantly related isolates from other regions. 788 
FIGURE 2. Phenotypic resistance of A. baumannii at high levels for all antimicrobial classes. 789 
(A) Resistance phenotypes measured on site at time of isolation clearly demonstrate the highly 790 
problematic levels of resistance in A. baumannii, with >70% non-sensitive against all tested 791 
classes. TZP, piperacillin-tazobactam; CFZ, cefazolin; CXMA, cefuroxime axetil; CRO, 792 
ceftriaxone; FEP, cefepime; DOR, doripenem; IPM, imipenem; MEM, meropenem; GEN, 793 
gentamicin; CIP, ciprofloxacin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole. (B) 794 
Distribution of antimicrobial resistance plasmids carried by A. baumannii in relation to 795 
sequence type (ST). (C) Distribution of acquired antimicrobial resistance genes carried by A. 796 
baumannii in relation to sequence type (ST). 797 
FIGURE 3. Properties of 46 GC2 A. baumannii Thai isolates belonging to the common capsule 798 
genotypes encountered in this study. (A) Motility measurements, capsule size, and C’ 799 
susceptibility in phylogenetic context. (B) C’ resistance profiles stratified by capsule type.  800 
FIGURE S1. Resistance genes and phenotypic resistance. The strains were grouped according 801 
to the number of agents in the Vitek screen the respective strains were resistant to, along the x-802 
axis. The y-axis shows the number of strains in the relevant class, the colour of the bars shows 803 
resistance (dark purple), intermediate (yellow) or sensitive (green) against the respective 804 
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antimicrobial of the subplot. This shows that almost all strains are resistant against 12 reagents, 805 
sensitivity of the highly-resistant ones on the far end of the x-scale is only occasionally in 806 
sulfonamides or tetracycline, but all are fully resistant against the β-lactam class.   807 
FIGURE S2. Presence of genes encoding antibiotic resistance in Thai A. baumannii isolates. 808 
The guidance tree is shown in Figure 3A. Bla, β-lactamases; AGly, aminoglycosides; MLS, 809 
macrolides; Phe, chloramphenicol; Rif, rifampin; Sul, sulfonamides; Tet, tetracycline; Tmt, 810 
trimethoprim. AMR genes were sourced from the curated version of the ARG-ANNOT 811 
database available at the SRST2 site. Isolates from Thammasat University Hospital, Siriraj 812 
Hospital, and Songklanagarind Hospital are designated TU, Siriraj, and Songkla, respectively. 813 
Sequence types are shown, as indicated in the legend. Chromosomal mutations for RpoB are 814 
also shown, we could detect potential resistance-conferring changes (Pérez-Varela et al., 815 
2017)(Giannouli et al., 2012) D525N, H535Q, and S540F. 816 
FIGURE S3. Cell surface polysaccharide diversity of A. baumannii Thai isolates. Capsular 817 
(KL) and outer core loci (OCL) in silico typing of Thai isolates. A. baumannii shows 818 
considerable variation in K-type and a more conserved distribution of OCL-types.  819 
FIGURE S4. Virulence genes associated with Thai A. baumannii isolates. The guidance tree 820 
is shown in Figure 3A. Antibiotic resistance genes were detected with the curated version of 821 
the ARG-ANNOT database available at the SRST2 site using ARIBA. Isolates from 822 
Thammasat University Hospital, Siriraj Hospital, and Songklanagarind Hospital are designated 823 
TU, Siriraj, and Songkla, respectively. Sequence types are shown, as indicated in the legend. 824 
Supporting datasets:  825 
Dataset S1: The custom-made plasmid replicon collection used to assign plasmid types to A. 826 
baumannii. 827 
  828 
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Table 1. Properties of GC2 A. baumannii clinical isolates 829 
 830 
aThamm: Thammasat Hospital; Songkla: Songklaragarind Hospital; Siriraj: Siriraj Hospital 831 
bComplement reactivity: R: Resistant; DS: Delayed susceptible; S: Rapidly susceptible 832 
cValues less than 10 mm are considered negative (Vijayakumar et al., 2016) 833 
dValues less than 5 mm are considered negative (Vijayakumar et al., 2016) 834 
Thai strain ID Hospital KL OCL ST Sample 
source 
Motility (mm) C' Susceptibilityb 
Swarmingc  Twitchingd  
ABMYSP-109 Thamma KL10 OCL1 2 Sputum £10 15 R 
ABMYH-1245 Thamm KL10 OCL1 2 Blood £10 10 R 
ABAPSP-55 Thamm KL10 OCL1 2 Sputum £10 5 R 
ABAPSP-64 Thamm KL10 OCL1 2 Sputum 12 12 R 
ABMYSP-101 Thamm KL10 OCL1 2 Sputum £10 5 R 
ABMYSP-182 Thamm KL10 OCL1 2 Sputum 14 <5 R 
ABMYSP-187 Thamm KL10 OCL1 2 Sputum 14 <5 R 
ABMYH-797 Thamm KL10 OCL1 2 Blood £10 10 R 
AB1039 Songkla KL2 OCL1 2 Sputum 19 <5 S 
AB1492-09 Songkla KL2 OCL1 2 Sputum 16 <5 R 
AB3396 Songkla KL2 OCL1 2 Tissue 15 <5 R 
AB4452-09 Songkla KL2 OCL1 2 Sputum £10 <5 DS 
AB11 Siriraj KL3 OCL1 2 Sputum £10 <5 R 
ABJNH-403 Thamm KL3 OCL1 2 Blood £10 10 R 
AB15 Siriraj KL47 OCL1 2 Sputum 15 5 R 
ABAPP-61 Thamm KL47 OCL1 2 Tissue 15 <5 R 
AB8 Siriraj KL49 OCL1 2 Sputum 15 <5 R 
AB14  Siriraj KL49 OCL1 2 Sputum 17 <5 R 
AB724  Songkla KL49 OCL1 2 Sputum 14 <5 R 
AB1719-09  Songkla KL49 OCL1 2 Tissue 15 <5 R 
AB2792 Songkla KL49 OCL1 2 Blood £10 10 R 
AB1 Siriraj KL52 OCL1 2 Tissue 14 <5 R 
ABMYSP-444 Thamm KL52 OCL1 2 Sputum £10 5 R 
AB6 Siriraj KL6 OCL1 2 Sputum 18 <5 R 
AB7 Siriraj KL6 OCL1 2 Sputum 17 <5 R 
AB9 Siriraj KL6 OCL1 2 Sputum 18 5 S 
ABMYSP-185 Thamm KL6 OCL1 2 Sputum £10 5 R 
ABMYSP-216 Thamm KL6 OCL1 2 Sputum 16 <5 R 
ABMYH-1652 Thamm KL6 OCL1 2 Blood £10 5 R 
ABMYSP-475 Thamm KL6 OCL1 2 Sputum 18 <5 R 
ABMYSP-477 Thamm KL6 OCL1 2 Sputum 15 <5 R 
ABMYSP-479 Thamm KL6 OCL1 2 Sputum 15 <5 R 
ABMYSP-517 Thamm KL6 OCL1 2 Sputum £10 <5 R 
ABMASP-366 Thamm KL6 OCL1 2 Sputum £10 5 R 
ABMASP-379 Thamm KL6 OCL1 2 Sputum £10 13 R 
ABMASP-491 Thamm KL6 OCL1 2 Sputum £10 <5 R 
ABAPSP-195 Thamm KL6 OCL1 2 Sputum £10 <5 R 
ABAPU-469 Thamm KL6 OCL1 2 Tissue 11 <5 R 
ABAPU-722 Thamm KL6 OCL1 2 Tissue 16 <5 R 
ABMYSP-494 Thamm KL6 OCL1 2 Sputum 16 <5 R 
ABMYSP-6 Thamm KL6 OCL1 2 Sputum 16 <5 S 
ABMYSP-207 Thamm KL6 OCL1 2 Sputum £10 <5 R 
ABMYSP-210 Thamm KL6 OCL1 2 Sputum £10 <5 S 
ABMYSP-245 Thamm KL6 OCL1 2 Sputum £10 <5 R 
ABMYH-1033 Thamm KL6 OCL1 2 Blood £10 10 R 







